Glucagonoma: From skin lesions to the neuroendocrine component (Review).
glucagon
glucagonoma
necrolytic migratory erythema
neuroendocrine
rush
somatostatin
Journal
Experimental and therapeutic medicine
ISSN: 1792-0981
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
14
04
2020
accepted:
15
05
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
ppublish
Résumé
Glucagonoma is a hormonally active rare pancreatic neuroendocrine tumour causing an excess of glucagon. This is a narrative review based on a multidisciplinary approach of the tumour. Typically associated dermatosis is necrolytic migratory erythema (NME) which is most frequently seen at disease onset. Insulin-dependent diabetes mellitus, depression, diarrhoea, deep vein thrombosis are also identified, as parts of so-called 'D' syndrome. Early diagnosis is life saving due to potential aggressive profile and high risk of liver metastasis. NME as paraneoplastic syndrome may be present for months and even years until adequate recognition and therapy; it is remitted after successful pancreatic surgery. Thus the level of practitioners' awareness is essential. If surgery is not curative, debulking techniques may improve the clinical aspects and even the outcome in association with other procedures such as embolization of hepatic metastasis; ablation of radiofrequency type; medical therapy including chemotherapy, targeted therapy with mTOR inhibitors such as everolimus, PRRT (peptide receptor radiotherapy), and somatostatin analogues (including combinations of medical treatments). Increased awareness of the condition involves multidisciplinary practitioners.
Identifiants
pubmed: 32905095
doi: 10.3892/etm.2020.8966
pii: ETM-0-0-8966
pmc: PMC7465236
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
3389-3393Informations de copyright
Copyright © 2020, Spandidos Publications.
Références
Peptides. 2015 May;67:74-81
pubmed: 25814364
J Dermatol. 2020 Feb;47(2):178-180
pubmed: 31829458
Case Rep Surg. 2016;2016:1484089
pubmed: 26981306
Annu Rev Med. 2015;66:1-16
pubmed: 25341008
Med Ultrason. 2011 Mar;13(1):15-20
pubmed: 21390338
Dis Markers. 2016;2016:9602472
pubmed: 27821903
Surg Oncol Clin N Am. 2016 Apr;25(2):363-74
pubmed: 27013370
Medicine (Baltimore). 2019 Sep;98(38):e17037
pubmed: 31567941
Endocr Pract. 2007 Nov-Dec;13(7):780-4
pubmed: 18194937
Clin Endocrinol (Oxf). 2011 May;74(5):658-60
pubmed: 21128995
Endocrinol Diabetes Metab Case Rep. 2019 Mar 5;2019:
pubmed: 30836327
Dermatol Ther. 2017 Jul;30(4):
pubmed: 28508546
Pancreas. 2019 Apr;48(4):e24-e26
pubmed: 30973467
Peptides. 2020 Mar;125:170197
pubmed: 31715213
Dis Markers. 2018 May 8;2018:9787831
pubmed: 29854027
Am J Dermatopathol. 2019 Mar;41(3):e29-e32
pubmed: 30124507
Endocr Pract. 2020 Feb;26(2):253
pubmed: 31170359
Acta Dermatovenerol Croat. 2018 Dec;26(4):329-332
pubmed: 30665484
Gastroenterol Hepatol. 2018 Oct;41(8):500-502
pubmed: 29074313
Rom J Morphol Embryol. 2012;53(2):401-5
pubmed: 22732814
Endocr Relat Cancer. 2016 Sep;23(9):R423-36
pubmed: 27461388
Curr Opin Endocrinol Diabetes Obes. 2020 Feb;27(1):2-10
pubmed: 31815785
Oncol Lett. 2018 Mar;15(3):2749-2755
pubmed: 29435000
J Cutan Med Surg. 2017 Nov/Dec;21(6):559-561
pubmed: 28662584
Medicine (Baltimore). 2019 Sep;98(37):e17158
pubmed: 31517863
Biomedica. 2016 Jun 03;36(2):176-81
pubmed: 27622478
N Engl J Med. 2017 Mar 9;376(10):e18
pubmed: 28273025
Biomark Med. 2016 Nov;10(11):1141-1151
pubmed: 27611762
Rom J Morphol Embryol. 2014;55(4):1437-41
pubmed: 25611278
Physiol Rev. 2017 Apr;97(2):721-766
pubmed: 28275047
J Pak Med Assoc. 2017 Jun;67(6):917-922
pubmed: 28585593
Surg Pathol Clin. 2014 Dec;7(4):559-75
pubmed: 26837555
BMJ Case Rep. 2019 Aug 10;12(8):
pubmed: 31401568
Arch Med Sci. 2017 Apr 1;13(3):515-524
pubmed: 28507564
Semin Diagn Pathol. 2019 Jul;36(4):211-228
pubmed: 30736994
Oncol Lett. 2015 Apr;9(4):1579-1582
pubmed: 25789004
World J Surg Oncol. 2019 Apr 11;17(1):66
pubmed: 30975157
Semin Diagn Pathol. 2019 Jul;36(4):240-245
pubmed: 31300257
Gland Surg. 2018 Feb;7(1):20-27
pubmed: 29629316
Int J Dermatol. 2018 Jun;57(6):642-645
pubmed: 29450880
J Eur Acad Dermatol Venereol. 2016 Dec;30(12):2016-2022
pubmed: 27422767
Semin Diagn Pathol. 2019 Jul;36(4):229-239
pubmed: 30910348
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
Hosp Pract (1995). 2016 Aug;44(3):109-19
pubmed: 27404266
Intern Med. 2018 Aug 1;57(15):2283-2284
pubmed: 29526932
J Am Acad Dermatol. 2013 Feb;68(2):e44-6
pubmed: 23317985
Autops Case Rep. 2019 Nov 27;9(4):e2019129
pubmed: 31807436
Indian J Dermatol Venereol Leprol. 2019 Aug 1;:
pubmed: 31368453
Rev Endocr Metab Disord. 2018 Jun;19(2):145-158
pubmed: 29464446
Rom J Morphol Embryol. 2013;54(3 Suppl):717-20
pubmed: 24322017
Oncol Lett. 2019 May;17(5):4102-4111
pubmed: 30944603
Bosn J Basic Med Sci. 2016 Feb 01;16(1):1-7
pubmed: 26773171
J Community Hosp Intern Med Perspect. 2019 Nov 1;9(5):425-429
pubmed: 31723389
J Pancreat Cancer. 2018 May 01;4(1):11-16
pubmed: 30631852
J Clin Transl Endocrinol. 2018 Dec 20;15:45-53
pubmed: 30619718
Clin Endocrinol (Oxf). 2011 May;74(5):593-8
pubmed: 21470282
Surg Today. 2015 Oct;45(10):1317-20
pubmed: 25373364
J Gastrointest Surg. 2020 Mar;24(3):701-703
pubmed: 31152349
Front Horm Res. 2015;44:24-39
pubmed: 26303702